MUK nine results: Intensive treatment delivers deep responses in ultra-high risk myeloma patients

In June, the first results from the OPTIMUM/MUK nine clinical trial were presented at international conferences.
The trial is the first to use state-of-the-art diagnostics and genetic profiling to screen for patients with high-risk myeloma.
These results show that treatment with a five-drug induction treatment (Dara-CVRd) and stem cell transplant is effective and well tolerated in ultra-high risk myeloma patient

A new UK study recruits MGUS and smouldering myeloma patients to discover what causes myeloma.

University College London has announced the launch of a new National Cancer Research Network observational study (COSMOS) that will recruit patients with MGUS (monoclonal gammopathy of undetermined significance) and smouldering myeloma to help identify the genetic and immunological changes that cause myeloma. This ground-breaking study, which is funded by Cancer Research UK and the Medical…

Leeds CTRU launches a series of webinars to introduce the UKMRA-Myeloma UK-Concept and Access Research Programme

The Clinical Trials Research Unit (CTRU) at the University of Leeds is running a series of webinars for researchers and clinicians so they can learn all about the UKMRA-Myeloma UK-Concept and Access Research Programme (CARP) and how it supports the development of early phase myeloma trials. The webinar series will include presentations that will describe…